Prime Medicine, Inc.PRMENASDAQ
Loading
Price to Sales: Premium ValuationElevated
Percentile Rank67
5Y CAGR-17.0%
Studio
Year-over-Year Change

Price-to-sales ratio

5Y CAGR
-17.0%/yr
Long-term compound
Percentile
P67
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive declineElevated
PeriodValueYoY Change
2025111.44-4.0%
2024116.10-
20230.00-
20220.00-
20210.00-100.0%
2020282.41-
20190.00-